A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
Status:
Completed
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
While the incidence of acute rejection and early graft loss have improved dramatically with
the advent of newer immunosuppressant medications, improvements in long-term patient and
allograft survival after kidney transplantation have not been achieved. The specific drug
combination that provides the best outcomes with the least amount of side effects is not
known. Each kidney transplant center uses the combination of drugs that they believe is
optimal. This study is about identifying whether drugs that are currently approved for use in
kidney transplantation can be used in a new combination safely and with potentially fewer
side effects than the drug combinations that are currently used at St. Paul's Hospital and
other transplant centres.